{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:49:06Z","timestamp":1773848946472,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"DOI":"10.1007\/s00392-026-02871-0","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:56:23Z","timestamp":1773042983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and tolerability of pharmacologic stress with the selective A2A adenosine receptor agonist regadenoson for the assessment of myocardial ischemia: results from 5780 consecutive patients in a cardiology practice"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2189-0593","authenticated-orcid":false,"given":"Sigmund","family":"Silber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Rippel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2871_CR1","unstructured":"Statistical Office (2022) Causes of deaths in 2020. Wiesbaden, Germany. https:\/\/www.destatis.de. Accessed October 2025."},{"key":"2871_CR2","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1093\/eurheartj\/ehy267","volume":"39","author":"J Knuuti","year":"2018","unstructured":"Knuuti J, Ballo H, Juarez-Orozco LE, Saraste A, Kolh P, Rutjes AWS, Juni P, Windecker S, Bax JJ, Wijns W (2018) The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J 39:3322\u20133330","journal-title":"Eur Heart J"},{"key":"2871_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, Group ESCSD (2020) 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41:407\u2013477","journal-title":"Eur Heart J"},{"key":"2871_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-15-85","volume":"15","author":"S Vasu","year":"2013","unstructured":"Vasu S, Bandettini WP, Hsu LY, Kellman P, Leung S, Mancini C, Shanbhag SM, Wilson J, Booker OJ, Arai AE (2013) Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson 15:85","journal-title":"J Cardiovasc Magn Reson"},{"key":"2871_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.nuclcard.2007.06.114","volume":"14","author":"AE Iskandrian","year":"2007","unstructured":"Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, Lieu H, Mahmarian JJ, Olmsted A, Underwood SR, Vitola J, Wang W, Investigators AM (2007) Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 14:645\u2013658","journal-title":"J Nucl Cardiol"},{"key":"2871_CR6","doi-asserted-by":"crossref","unstructured":"Frey SM, Honegger U, Clerc OF, Caobelli F, Haaf P, Zellweger MJ (2022) Left ventricular ejection fraction, myocardial blood flow and hemodynamic variables in adenosine and regadenoson vasodilator 82-Rubidium PET. J Nucl Cardiol 29: 921\u2013933","DOI":"10.1007\/s12350-021-02729-0"},{"key":"2871_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12350-014-9981-6","volume":"22","author":"JJ Mahmarian","year":"2015","unstructured":"Mahmarian JJ, Peterson LE, Xu J, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Nabi F (2015) Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials. J Nucl Cardiol 22:248\u2013261","journal-title":"J Nucl Cardiol"},{"key":"2871_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jcmg.2009.04.011","volume":"2","author":"JJ Mahmarian","year":"2009","unstructured":"Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, Moye LA, Olmsted AW (2009) Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2:959\u2013968","journal-title":"JACC Cardiovasc Imaging"},{"key":"2871_CR9","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.jacc.2005.05.097","volume":"46","author":"RC Hendel","year":"2005","unstructured":"Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, Mahmarian JJ (2005) Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 46:2069\u20132075","journal-title":"J Am Coll Cardiol"},{"key":"2871_CR10","unstructured":"Kontraindikation Adenosin (n.d). https:\/\/www.gelbe-liste.de\/wirkstoffe\/Adenosin_10221. Accessed Oct 2025"},{"key":"2871_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10554-021-02374-1","volume":"38","author":"K Ananthasubramaniam","year":"2022","unstructured":"Ananthasubramaniam K, Saval M, Van Harn M, Kitt TM, Kristy RM, Xu Y, Spalding JR (2022) Clinical experience with regadenoson SPECT myocardial perfusion imaging: insights into patient characteristics, safety, and impact of results on clinical management. Int J Cardiovasc Imaging 38:257\u2013267","journal-title":"Int J Cardiovasc Imaging"},{"key":"2871_CR12","first-page":"2046","volume":"28","author":"T Asif","year":"2021","unstructured":"Asif T, Lee Chuy K, Malhotra S (2021) Asystole following regadenoson administration: review of literature, risk factors and management. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol 28:2046\u20132055","journal-title":"J Nucl Cardiol Off Publ Am Soc Nucl Cardiol"},{"key":"2871_CR13","first-page":"698","volume":"27","author":"MH Mustehsan","year":"2020","unstructured":"Mustehsan MH, Gandhi H, Hasani A, Rashid SMI, Goldberg Y (2020) Regadenoson-induced asystole and ischemic EKG changes in the setting of underlying coronary disease. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol 27:698\u2013701","journal-title":"J Nucl Cardiol Off Publ Am Soc Nucl Cardiol"},{"key":"2871_CR14","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jcmg.2019.01.017","volume":"12","author":"LA Derbas","year":"2019","unstructured":"Derbas LA, Thomas GS, Medina CA, Abdel-Karim AA, Saeed IM, Bateman TM (2019) Severe bradycardia and asystole following regadenoson in pharmacological myocardial perfusion imaging: cases and treatment recommendations. JACC Cardiovasc Imaging 12:1288\u20131290","journal-title":"JACC Cardiovasc Imaging"},{"key":"2871_CR15","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s12350-014-9898-0","volume":"21","author":"J Rosenblatt","year":"2014","unstructured":"Rosenblatt J, Mooney D, Dunn T, Cohen M (2014) Asystole following regadenoson infusion in stable outpatients. J Nucl Cardiol 21:862\u2013868","journal-title":"J Nucl Cardiol"},{"key":"2871_CR16","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s12350-014-9968-3","volume":"21","author":"SR Underwood","year":"2014","unstructured":"Underwood SR, Latus KA, Reyes E, Standbridge K, Walker S, Wechalekar K (2014) Regadenoson-induced bradycardia and hypotension: possible mechanism and antidote. J Nucl Cardiol 21:1040","journal-title":"J Nucl Cardiol"},{"key":"2871_CR17","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/s12350-012-9610-1","volume":"19","author":"A Pandit","year":"2012","unstructured":"Pandit A, Unzek Freiman S (2012) Complete heart block associated with regadenoson: a real side effect. J Nucl Cardiol 19:1236\u20131239","journal-title":"J Nucl Cardiol"},{"key":"2871_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s12350-017-1081-y","volume":"26","author":"E Andrikopoulou","year":"2019","unstructured":"Andrikopoulou E, Morgan CJ, Brice L, Bajaj NS, Doppalapudi H, Iskandrian AE, Hage FG (2019) Incidence of atrioventricular block with vasodilator stress SPECT: a meta-analysis. J Nucl Cardiol 26:616\u2013628","journal-title":"J Nucl Cardiol"},{"key":"2871_CR19","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1007\/s12350-017-1174-7","volume":"25","author":"V Agrawal","year":"2018","unstructured":"Agrawal V, Hosey C, Smith GT, Shah C (2018) Detrimental effects of nitroglycerin use during regadenoson vasodilator stress testing: a cautionary tale. J Nucl Cardiol 25:1718\u20131723","journal-title":"J Nucl Cardiol"},{"key":"2871_CR20","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s12350-016-0452-0","volume":"24","author":"JA Doran","year":"2017","unstructured":"Doran JA, Sajjad W, Schneider MD, Gupta R, Mackin ML, Schwartz RG (2017) Aminophylline and caffeine for reversal of adverse symptoms associated with regadenoson SPECT MPI. J Nucl Cardiol 24:1062\u20131070","journal-title":"J Nucl Cardiol"},{"key":"2871_CR21","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s12350-016-0484-5","volume":"24","author":"AF Jolly","year":"2017","unstructured":"Jolly AF, Thomas GS (2017) Intravenous caffeine: an alternative to aminophylline to reverse adverse effects during regadenoson myocardial perfusion imaging. J Nucl Cardiol 24:1071\u20131074","journal-title":"J Nucl Cardiol"},{"key":"2871_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12350-012-9533-x","volume":"19","author":"R Doukky","year":"2012","unstructured":"Doukky R, Morales Demori R, Jain S, Kiriakos R, Mwansa V, Calvin JE (2012) Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. \u201cThe ASSUAGE trial.\u201d J Nucl Cardiol 19:448\u2013457","journal-title":"J Nucl Cardiol"},{"key":"2871_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.nuclcard.2008.02.013","volume":"15","author":"GS Thomas","year":"2008","unstructured":"Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, Mathur V (2008) Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 15:319\u2013328","journal-title":"J Nucl Cardiol"},{"key":"2871_CR24","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12350-012-9547-4","volume":"19","author":"BM Prenner","year":"2012","unstructured":"Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE (2012) A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 19:681\u2013692","journal-title":"J Nucl Cardiol"},{"key":"2871_CR25","first-page":"283","volume":"35","author":"C Salgado-Garcia","year":"2016","unstructured":"Salgado-Garcia C, Jimenez-Heffernan A, Ramos-Font C, Lopez-Martin J, Sanchez-de-Mora E, Aroui T, Lopez-Aguilar R, Rivera-de-Los-Santos F, Ruiz-Frutos C (2016) Safety of regadenoson in patients with severe chronic obstructive pulmonary disease. Rev Esp Med Nucl Imagen Mol 35:283\u2013286","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"2871_CR26","first-page":"129","volume":"9","author":"Y Golzar","year":"2014","unstructured":"Golzar Y, Doukky R (2014) Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge. Int J Chron Obstruct Pulmon Dis 9:129\u2013137","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2871_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.nuclcard.2008.02.009","volume":"15","author":"BR Leaker","year":"2008","unstructured":"Leaker BR, O\u2019Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, Lieu HD (2008) Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 15:329\u2013336","journal-title":"J Nucl Cardiol"},{"key":"2871_CR28","volume":"2019","author":"SS Radwan","year":"2019","unstructured":"Radwan SS, Schwartz OG (2019) Seizure: an adverse effect of regadenoson in myocardial perfusion imaging. Case Rep Cardiol 2019:6240605","journal-title":"Case Rep Cardiol"},{"key":"2871_CR29","first-page":"869","volume":"21","author":"V Agarwal","year":"2014","unstructured":"Agarwal V, DePuey EG (2014) Regadenoson and seizures: a real clinical concern. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol 21:869\u2013870","journal-title":"J Nucl Cardiol Off Publ Am Soc Nucl Cardiol"},{"issue":"2","key":"2871_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s12350-011-9461-1","volume":"19","author":"RL Page 2nd","year":"2012","unstructured":"Page RL 2nd, Spurck P, Bainbridge JL, Michalek J, Quaife RA (2012) Seizures associated with regadenoson: a case series. J Nucl Cardiol 19(2):389\u2013391","journal-title":"J Nucl Cardiol"},{"key":"2871_CR31","unstructured":"Rapiscan (Regadenoson) (2014) Wichtige neue Hinweise zur Minimierung des Risikos einesSchlaganfalls und einer Verl\u00e4ngerung von Rapiscan-bedingten Anf\u00e4llen nach der Anwendung von Aminophyllin. https:\/\/www.akdae.de\/Arzneimittelsicherheit\/RHB\/Archiv\/2014\/20141222.pdf. Accessed Oct 2025"},{"key":"2871_CR32","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1007\/s12350-021-02736-1","volume":"29","author":"M Elsadany","year":"2022","unstructured":"Elsadany M, McMahon SR, Mehla S, Duvall WL (2022) Hemiplegic migraine episode triggered by regadenoson. J Nucl Cardiol 29:3469\u20133473","journal-title":"J Nucl Cardiol"},{"key":"2871_CR33","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2009.04.089","volume":"54","author":"W Al Jaroudi","year":"2009","unstructured":"Al Jaroudi W, Iskandrian AE (2009) Regadenoson: a new myocardial stress agent. J Am Coll Cardiol 54:1123\u20131130","journal-title":"J Am Coll Cardiol"},{"key":"2871_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2217\/pgs-2016-0178","volume":"18","author":"M Berlacher","year":"2017","unstructured":"Berlacher M, Mastouri R, Philips S, Skaar TC, Kreutz RP (2017) Common genetic polymorphisms of adenosine A2A receptor do not influence response to regadenoson. Pharmacogenomics 18:523\u2013529","journal-title":"Pharmacogenomics"},{"key":"2871_CR35","volume":"13","author":"KO Elkholy","year":"2021","unstructured":"Elkholy KO, Hegazy O, Okunade A, Aktas S, Ajibawo T (2021) Regadenoson stress testing: a comprehensive review with a focused update. Cureus 13:e12940","journal-title":"Cureus"},{"key":"2871_CR36","first-page":"135","volume":"329","author":"ME Olah","year":"1995","unstructured":"Olah ME, Ren H, Stiles GL (1995) Adenosine receptors: protein and gene structure. Arch Int Pharmacodyn Ther 329:135\u2013150","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"2871_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1146\/annurev.pa.35.040195.003053","volume":"35","author":"ME Olah","year":"1995","unstructured":"Olah ME, Stiles GL (1995) Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 35:581\u2013606","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2871_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3413\/Nukmed-2017040001","volume":"56","author":"O Lindner","year":"2017","unstructured":"Lindner O, Bengel F, Burchert W, Dorr R, Hacker M, Schafer W, Schafers MA, Schmidt M, Schwaiger M, Vom Dahl J, Zimmermann R (2017) Myokard-perfusions-SPECT. Myocardial perfusion SPECT - Update S1 guideline. Nuklearmedizin 56:115\u2013123","journal-title":"Nuklearmedizin"},{"key":"2871_CR39","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/0735-1097(95)00011-R","volume":"25","author":"DJ Pennell","year":"1995","unstructured":"Pennell DJ, Mavrogeni SI, Forbat SM, Karwatowski SP, Underwood SR (1995) Adenosine combined with dynamic exercise for myocardial perfusion imaging. J Am Coll Cardiol 25:1300\u20131309","journal-title":"J Am Coll Cardiol"},{"key":"2871_CR40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1517\/17530059.2010.506909","volume":"4","author":"E Reyes","year":"2010","unstructured":"Reyes E, Pennell DJ (2010) Regadenoson for myocardial perfusion scintigraphy. Expert Opin Med Diagn 4:447\u2013454","journal-title":"Expert Opin Med Diagn"},{"key":"2871_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/CRD.0b013e3182613db6","volume":"21","author":"G Palani","year":"2013","unstructured":"Palani G, Ananthasubramaniam K (2013) Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications. Cardiol Rev 21:42\u201348","journal-title":"Cardiol Rev"},{"key":"2871_CR42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0022-3565(24)29370-8","volume":"298","author":"Z Gao","year":"2001","unstructured":"Gao Z, Li Z, Baker SP, Lasley RD, Meyer S, Elzein E, Palle V, Zablocki JA, Blackburn B, Belardinelli L (2001) Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther 298:209\u2013218","journal-title":"J Pharmacol Exp Ther"},{"key":"2871_CR43","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jcmg.2013.03.001","volume":"6","author":"A Pollack","year":"2013","unstructured":"Pollack A, Nazif T, Mancini D, Weisz G (2013) Detection and imaging of cardiac allograft vasculopathy. JACC Cardiovasc Imaging 6:613\u2013623","journal-title":"JACC Cardiovasc Imaging"},{"key":"2871_CR44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ijcard.2021.03.010","volume":"333","author":"MK Burrage","year":"2021","unstructured":"Burrage MK, Shanmuganathan M, Masi A, Hann E, Zhang Q, Popescu IA, Soundarajan R, Leal Pelado J, Chow K, Neubauer S, Piechnik SK, Ferreira VM (2021) Cardiovascular magnetic resonance stress and rest T1-mapping using regadenoson for detection of ischemic heart disease compared to healthy controls. Int J Cardiol 333:239\u2013245","journal-title":"Int J Cardiol"},{"key":"2871_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.rxeng.2020.01.002","volume":"62","author":"G Bastarrika","year":"2020","unstructured":"Bastarrika G, Ezponda A, Baizan AG, Calvo M, Pueyo JC, Gavira JJ, Caballeros M (2020) Safety of regadenoson for vasodilation in cardiac MRI stress tests. Radiologia (Engl Ed) 62:213\u2013221","journal-title":"Radiologia (Engl Ed)"},{"key":"2871_CR46","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3109\/14017431.2016.1163415","volume":"50","author":"M Pape","year":"2016","unstructured":"Pape M, Zacho HD, Aaroe J, Eggert Jensen S, Petersen LJ (2016) Safety and tolerability of regadenoson for myocardial perfusion imaging - first Danish experience. Scand Cardiovasc J 50:180\u2013186","journal-title":"Scand Cardiovasc J"},{"key":"2871_CR47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5455\/aim.2016.24.405-408","volume":"24","author":"N Beslic","year":"2016","unstructured":"Beslic N, Milardovic R, Sadija A, Ceric S, Raic Z (2016) Regadenoson in myocardial perfusion study - first institutional experiences in Bosnia and Herzegovina. Acta Inform Med 24:405\u2013408","journal-title":"Acta Inform Med"},{"key":"2871_CR48","first-page":"232","volume":"20","author":"J Koutsikos","year":"2017","unstructured":"Koutsikos J, Angelidis G, Zafeirakis A, Mamarelis I, Vogiatzis M, Ilia E, Lazaridis K, Demakopoulos N (2017) Performance and safety profile of regadenoson myocardial perfusion imaging: first experience in Greece. Hell J Nucl Med 20:232\u2013236","journal-title":"Hell J Nucl Med"},{"key":"2871_CR49","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.remnie.2014.07.005","volume":"33","author":"PL Jager","year":"2014","unstructured":"Jager PL, Buiting M, Mouden M, Oostdijk AH, Timmer J, Knollema S (2014) Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands. Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition) 33:346\u2013351","journal-title":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"},{"key":"2871_CR50","first-page":"2799","volume":"28","author":"AJ Kattoor","year":"2021","unstructured":"Kattoor AJ, Kolkailah AA, Iskander F, Iskander M, Diep L, Khan R, Doukky R (2021) The prognostic value of regadenoson SPECT myocardial perfusion imaging: the largest cohort to date. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol 28:2799\u20132807","journal-title":"J Nucl Cardiol Off Publ Am Soc Nucl Cardiol"},{"key":"2871_CR51","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1007\/s12350-020-02208-y","volume":"28","author":"GS Sidhu","year":"2021","unstructured":"Sidhu GS, Hendel RC (2021) The evolution of the prognostic value of regadenoson SPECT myocardial perfusion imaging. J Nucl Cardiol 28:2808\u20132811","journal-title":"J Nucl Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02871-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02871-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02871-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:02:54Z","timestamp":1773828174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02871-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":51,"alternative-id":["2871"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02871-0","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"25 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update because of a typesetting mistake, where a paragraph was inserted in its corrected and uncorrected form - the latter has been deleted now.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}